Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDerwent London Regulatory News (DLN)

Share Price Information for Derwent London (DLN)

Share Price is delayed by 15 minutes
Get Live Data
1,765.00    -13.00 (-0.73%)
Bid:
1,768.00
Ask:
1,771.00
Spread: 3.00 (0.17%)
Market Cap: £1.98b
DLN Live PriceLast checked at - London Stock Exchange

Intraday Derwent London Share Chart

Burberry extends commitment to Horseferry House

9 Dec 2025 07:00

RNS Number : 7070K
Derwent London PLC
09 December 2025
 

 

Derwent London plc ("Derwent London" / "the Group")

Burberry extends commitment to Horseferry House SW1

Derwent London is pleased to announce that it has regeared its lease with Burberry, the FTSE 100 British luxury brand, at Horseferry House SW1, extending the lease term to 2043 and incorporating two new five-yearly fixed uplifts.

Burberry's lease has been extended from 2038 to 2043 (without breaks), increasing the unexpired term to an attractive 17.6 years. New fixed uplifts replace the previous 2033 rent review and 2038 expiry, giving the Group visibility on future income. Under IFRS, the fixed uplifts will be recognised on a straight-line basis through the income statement, resulting in an immediate increase in earnings of c.£0.9m pa.

Paul Williams, Chief Executive of Derwent London, said:

"We have a strong, long-standing relationship with Burberry, one of our largest occupiers, who recently completed a comprehensive refit of Horseferry House. I am pleased that we have agreed to extend their lease to 2043, reflecting their long-term commitment to the building which serves as their global HQ. Since the start of the year, we have completed regear and renewal activity totalling £19.2m, averaging 5.1% above the previous rent."

 

For further information, please contact:

Derwent London

Tel: +44 (0)20 3478 4217 (Robert Duncan)

Paul Williams, Chief Executive

Richard Dean, Director of Investment

Robert Duncan, Head of Investor Relations

Brunswick Group

Tel: +44 (0)20 7404 5959

Nina Coad

Peter Hesse

 

 

 

 

 

Notes to editors

Derwent London plc

Derwent London plc owns a commercial real estate portfolio predominantly in central London valued at £5.2 billion as at 30 June 2025, making it the largest London office-focused real estate investment trust (REIT).

Our experienced team has a long track record of creating value throughout the property cycle by regenerating our buildings via redevelopment or refurbishment, effective asset management and capital recycling. We typically acquire central London properties off-market with low capital values and modest rents in improving locations, most of which are either in the West End or City Borders. We capitalise on the unique qualities of each of our properties - taking a fresh approach to the regeneration of every building with a focus on anticipating tenant requirements and an emphasis on design. Reflecting and supporting our long-term success, the business has a strong balance sheet with modest leverage, a robust income stream and flexible financing.

We are frequently recognised in industry awards for the quality, design and innovation of our projects. Landmark buildings in our 5.3 million sq ft portfolio include 25 Baker Street W1, 1 Soho Place W1, 80 Charlotte Street W1, Brunel Building W2, White Collar Factory EC1, Angel Building EC1 and Tea Building E1.

As part of our commitment to lead the industry in mitigating climate change, Derwent London has committed to becoming a net zero carbon business by 2030, publishing its pathway to achieving this goal in 2020. Our science-based carbon targets have been validated by the Science Based Targets initiative (SBTi). In 2013, we launched a voluntary Community Fund which to date has supported 180 community projects in central London.

The Company is a public limited company, which is listed on the London Stock Exchange and incorporated and domiciled in the UK. The address of its registered office is 25 Savile Row, London, W1S 2ER.

For further information see www.derwentlondon.com or follow us on LinkedIn.

Forward-looking statements

This document contains certain forward-looking statements about the future outlook of Derwent London. By their nature, any statements about future outlook involve risk and uncertainty because they relate to events and depend on circumstances that may or may not occur in the future. Actual results, performance or outcomes may differ materially from any results, performance or outcomes expressed or implied by such forward-looking statements.

No representation or warranty is given in relation to any forward-looking statements made by Derwent London, including as to their completeness or accuracy. Derwent London does not undertake to update any forward-looking statements whether as a result of new information, future events or otherwise. Nothing in this announcement should be construed as a profit forecast.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCBLBDDXBGDGUI
Date   Source Headline
2nd Jun 20262:00 pmRNSHolding(s) in Company
1st Jun 20267:00 amRNSTransaction in Own Shares
29th May 20265:37 pmRNSTotal Voting Rights
26th May 20267:00 amRNSTransaction in Own Shares
21st May 20265:15 pmRNSDirector/PDMR Shareholding
19th May 202610:00 amRNSDirector Declaration
18th May 20267:00 amRNSTransaction in Own Shares
15th May 202611:45 amRNSResult of AGM
12th May 20267:00 amRNSTrading Statement
1st May 202610:30 amRNSHolding(s) in Company
30th Apr 20264:45 pmRNSTotal Voting Rights
22nd Apr 20265:00 pmRNSHolding(s) in Company
22nd Apr 202610:15 amRNSHolding(s) in Company
20th Apr 202610:30 amRNSHolding(s) in Company
14th Apr 202611:14 amRNSAnnual Financial Report
10th Apr 20264:45 pmRNSAdmission to Trading
7th Apr 20265:12 pmRNSEmployee Benefit Trust (“EBT”)
7th Apr 20264:45 pmRNSDirector/PDMR Shareholding
2nd Apr 20267:00 amRNSAppointment of Barclays as joint corporate broker
1st Apr 20267:00 amRNSDisposal of Horseferry House SW1
31st Mar 20264:45 pmRNSTotal Voting Rights
27th Mar 202612:45 pmRNSDirector/PDMR Shareholding
24th Mar 202610:30 amRNSDirector/PDMR Shareholding
20th Mar 20264:15 pmRNSDirector/PDMR Shareholding
16th Mar 20267:00 amRNSNetwork building fully pre-let
16th Mar 20267:00 amRNSNetwork building fully pre-let
27th Feb 20264:45 pmRNSTotal Voting Rights
26th Feb 20267:32 amRNSDerwent London plc Disposal of 90 Whitfield Street
26th Feb 20267:00 amRNSResults for the Year Ended 31 December 2025
6th Feb 20264:40 pmRNSHolding(s) in Company
6th Feb 20267:00 amRNSDisposal of 80-85 Tottenham Court Road W1
30th Jan 20264:45 pmRNSTotal Voting Rights
22nd Jan 20269:00 amRNSDirectorate change
15th Jan 202611:00 amRNSHolding(s) in Company
31st Dec 20251:15 pmRNSTotal Voting Rights
31st Dec 20251:15 pmRNSTotal Voting Rights
17th Dec 20257:00 amRNSPlanning success at Blue Star House SW9
9th Dec 20257:00 amRNSBurberry extends commitment to Horseferry House
28th Nov 20254:45 pmRNSTotal Voting Rights
6th Nov 20257:00 amRNSThird Quarter Business Update
31st Oct 20254:45 pmRNSTotal Voting Rights
21st Oct 20257:00 amRNSStrategic partnership at Old Street Quarter
9th Oct 20257:00 amRNSSuccessful completion of 25 Baker Street
30th Sep 20254:45 pmRNSTotal Voting Rights
30th Sep 202511:00 amRNSHolding(s) in Company
22nd Sep 202512:00 pmRNSBlock listing Interim Review
9th Sep 202511:45 amRNSDirector Declaration
2nd Sep 202511:30 amRNSHolding(s) in Company
29th Aug 20254:45 pmRNSTotal Voting Rights
12th Aug 20257:00 amRNSBoard Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.